Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of DAPA-HF are confirming the original effect size in real-world data.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray et al. · New England Journal of Medicine · 2019
· openalex W2974260792
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0362
Recent follow-up analyses of PARADIGM-HF are confirming the original effect size in real-world data.
0.0617
Recent follow-up analyses of EMPEROR-Reduced are confirming the original effect size in real-world data.
0.1053
Recent follow-up analyses of ORBITA are confirming the original effect size in real-world data.
0.1086
Recent follow-up analyses of DAWN are confirming the original effect size in real-world data.
0.1150
Recent follow-up analyses of ISCHEMIA are confirming the original effect size in real-world data.
0.1175
The DAPA-HF trial's stated primary conclusion — Dapagliflozin reduces heart-failure worsening and CV death in HFrEF with or without diabetes. — replicates in independent cohorts.